Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

• Market Cap: $105.54M
• Dividend Yield: N/A
• Average Volume (3M): 4.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: -100.00%
• EPS Growth: -17.10%
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 24,544,905
• 10 Day Avg. Volume: 12,277,267
• 30 Day Avg. Volume: 4,166,063
• PEG Ratio: -0.01
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 978.41
• P/FCF Ratio: -4.41
• Enterprise Value/Market Cap: -0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 139.47
• Enterprise Value/Ebitda: 1.12
• 1Y Price Target: $16.50
• Price Target Upside: 283.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $5.00 ▲(16.28% Upside)

Artiva Biotherapeutics' stock score is primarily influenced by its financial challenges, despite positive technical indicators and promising clinical trial results. The negative valuation metrics further weigh on the overall score.

Positive Factors

Clinical Trial Success

Successful trial results for AlloNK enhance Artiva's competitive position in the NK cell therapy market, supporting future growth and potential FDA interactions.

Employee Retention Strategy

The RSU exchange program aligns employee interests with shareholders, potentially improving retention and motivation, which is crucial for long-term operational success.

Equity Improvement

Improved equity indicates enhanced financial stability, providing a stronger foundation for future operations and potential investment opportunities.

Negative Factors

Profitability Challenges

Significant net losses and negative profit margins highlight ongoing operational challenges, which could hinder sustainable growth and financial health.

Cash Flow Issues

Negative free cash flow indicates difficulties in generating cash, necessitating reliance on external funding, which may affect long-term financial flexibility.

Revenue Decline

The decline in revenue suggests challenges in product commercialization and market penetration, impacting the company's ability to scale and achieve profitability.

Artiva Biotherapeutics, Inc. Business Overview & Revenue Model

Company Description

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

How the Company Makes Money

Artiva Biotherapeutics generates revenue primarily through the development and commercialization of its cell therapy products. The company may secure funding through various channels, including equity financing, grants, and collaborations with larger pharmaceutical companies. Key revenue streams could include upfront payments, milestone payments, and royalties from partnerships and licensing agreements related to its NK cell therapy products. Additionally, Artiva could generate income through clinical trial collaborations and research agreements aimed at advancing its therapeutic candidates, as well as potential future sales of approved therapies once they enter the market.

Artiva Biotherapeutics, Inc. Financial Statement Overview

Summary

Artiva Biotherapeutics, Inc. is experiencing revenue growth and improvements in equity, yet continues to face profitability and cash flow challenges. The company demonstrates potential in its revenue trajectory, but operational inefficiencies and reliance on external financing pose significant risks.

Income Statement

Artiva Biotherapeutics, Inc. has demonstrated significant revenue growth from $2,002,000 in 2021 to $251,000 in 2024, indicating a positive trajectory. However, the company is still facing substantial net losses, with a net profit margin of -232.9% in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows improvement in stockholders' equity, moving from negative to positive in 2024, but the company still has a high debt-to-equity ratio due to previous negative equity. The equity ratio improved to 89.1% in 2024, showing enhanced financial stability despite previous challenges.

Cash Flow

Cash flow analysis indicates difficulties in generating positive free cash flow, with a free cash flow of -$55.7 million in 2024. The operating cash flow to net income ratio is negative, pointing to challenges in converting earnings to cash. There is a growth in financing cash flow, reflecting reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	251.00K	33.49M	4.93M	2.00M	0.00
Gross Profit	-662.00K	251.00K	33.49M	4.93M	2.00M	0.00
EBITDA	-82.23M	-64.85M	-28.41M	-58.67M	-71.58M	-17.52M
Net Income	-72.31M	-58.49M	-27.70M	-58.39M	-71.83M	-17.99M
Balance Sheet
Total Assets	148.86M	209.58M	105.11M	133.05M	169.93M	29.23M
Cash, Cash Equivalents and Short-Term Investments	122.97M	185.43M	76.97M	102.53M	160.92M	25.44M
Total Debt	11.69M	14.35M	16.91M	19.45M	1.74M	2.12M
Total Liabilities	19.64M	22.94M	267.13M	273.75M	258.78M	50.80M
Stockholders Equity	129.22M	186.64M	-162.01M	-140.70M	-88.86M	-21.57M
Cash Flow
Free Cash Flow	-78.91M	-55.67M	-50.69M	-57.13M	-17.03M	-13.82M
Operating Cash Flow	-76.67M	-55.03M	-47.43M	-50.83M	-15.30M	-13.54M
Investing Cash Flow	46.41M	-120.46M	-25.98M	-6.30M	-1.72M	-284.00K
Financing Cash Flow	100.00K	162.23M	24.39M	-1.26M	152.75M	37.40M

Artiva Biotherapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Positive. The current price of 4.3 is above the 20-day moving average (MA) of 3.91, above the 50-day MA of 3.91, and above the 200-day MA of 2.94, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 53.24 is Neutral, neither overbought nor oversold. The STOCH value of 30.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARTV.

Artiva Biotherapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	60 Neutral	$109.93M	-1.51	-49.78%	―	-82.16%	14.58%
ARTV	58 Neutral	$105.54M	-1.32	-47.96%	―	-100.00%	-17.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABVC	43 Neutral	$56.62M	-10.44	-40.32%	―	56.52%	75.22%
PLRX	37 Underperform	$75.58M	-0.43	-64.27%	―	―	14.19%
JSPR	35 Underperform	$51.21M	-0.31	-191.12%	―	―	-24.38%
ACET	27 Underperform	$79.57M	-0.41	-71.73%	―	―	25.89%

Artiva Biotherapeutics, Inc. Corporate Events

Artiva Biotherapeutics Executes RSU Exchange for Employees

On December 10-11, 2025, Artiva Biotherapeutics, Inc. executed Option for RSU Exchange Agreements with select employees, including top executives, to exchange underwater stock options for restricted stock units (RSUs) under the 2024 Equity Incentive Plan. This initiative, approved by the Board, aims to enhance employee retention and align their interests with shareholders by providing equity awards with current value and vesting terms. The RSU grants became effective on December 12, 2025, with specific vesting schedules and conditions for acceleration in case of termination or resignation.

Artiva Biotherapeutics Reports Positive AlloNK Trial Results

On November 12, 2025, Artiva Biotherapeutics announced positive initial safety and translational data from clinical trials of AlloNK in combination with rituximab or obinutuzumab for treating autoimmune diseases. The trials demonstrated that AlloNK was well tolerated, with no serious adverse events, and showed consistent B-cell depletion, comparable to CD19-auto-CAR-T therapies. This data supports the feasibility of administering AlloNK in outpatient and community settings, potentially addressing unmet needs in refractory rheumatoid arthritis, with plans for further clinical response data and FDA interactions in 2026.